David O. Calligaro

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 365 citations · Full text

Robust Central Reduction, Amyloid-β Peptide, Neurochemical Biomarkers +21

Adipsin, a Biomarker of Gastrointestinal Toxicity Mediated by a Functional γ-Secretase Inhibitor

George H. Searfoss, William H. Jordan, David O. Calligaro et al. · Journal of Biological Chemistry · 2003 · 336 citations · Full text

Preclinical pharmacological profile of the selective 5-HT_1Freceptor agonist lasmiditan

David L. Nelson, Lee A. Phebus, Kirk W. Johnson et al. · Cephalalgia · 2010 · 207 citations

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 195 citations · Full text

Amyloid β, Neurodegenerative Diseases, Amyloid Lowering +15

Olanzapine: a basic science update

F.P. Bymaster, Kenneth W. Perry, David L. Nelson et al. · The British Journal of Psychiatry · 1999 · 149 citations

Neuropsychology, Psychotropic Medication, Psychopharmacology +16